Latest press release: The company has comitted to further research in Optina and Ampio and Zertane is in a quiet period of some sort AND if it is sold then we longs might enjoy a nice payday IMO. Either way this company is going places, what if all three show success?
Recent article says cah burn from these additional trials will require another secondary offering in the first half of 2013. If we start to see some positive spins on things, it will be a sign they are looking to raise the PPS to do the offering. Usually their offerings have been at a 20 - 25% discount to the market. Need more time with AMPE to decide.
Yep another hit piece just today written from a guy who is short AMPE, if anything the stock is oversold, closer to 52 week low than the high, and guess what they have two important drugs coming to trials. So now it is time to ride the wave of shorts?
They only need one to rocket the stock but I believe they are going to hit at least two and very likely all three. Plus they are accelerating a very exciting new class of cancer drug NCE001. And don't forget about the ORP diagnostic. The 5,000 patient trial is finished and I believe they are getting ready to announce something major.